AbbVie Other Eye Care — Net revenues increased by 18.5% to $294.00M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 36.7%, from $215.00M to $294.00M. Over 4 years (FY 2021 to FY 2025), Other Eye Care — Net revenues shows a downward trend with a -3.6% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
An increase indicates growing market adoption or successful commercialization of secondary eye care products, while a decrease may signal market saturation, increased competition, or product lifecycle maturity.
This metric represents the total net revenue generated from the sale of pharmaceutical products within the company's spe...
Peers in the pharmaceutical industry typically report similar revenue streams under specialized ophthalmology or eye care segments, often categorized by therapeutic area or product franchise.
abbv_segment_other_eye_care_net_revenues| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $301.00M | $286.00M | $306.00M | $278.00M | $327.00M | $287.00M | $283.00M | $200.00M | $215.00M | $207.00M | $181.00M | $200.00M | $225.00M | $207.00M | $215.00M | $217.00M | $250.00M | $248.00M | $294.00M |
| QoQ Change | — | -5.0% | +7.0% | -9.2% | +17.6% | -12.2% | -1.4% | -29.3% | +7.5% | -3.7% | -12.6% | +10.5% | +12.5% | -8.0% | +3.9% | +0.9% | +15.2% | -0.8% | +18.5% |
| YoY Change | — | — | — | — | +8.6% | +0.3% | -7.5% | -28.1% | -34.3% | -27.9% | -36.0% | +0.0% | +4.7% | +0.0% | +18.8% | +8.5% | +11.1% | +19.8% | +36.7% |
We use cookies for analytics. See our Privacy and Cookie Policy.